BioStock: Norwegian doctors prepare for Idogen’s study

Biotech company Idogen is in full swing with preparations for the first clinical study with the cell therapy IDO 8 in patients with severe haemophilia A. BioStock had the opportunity to interview Professor Pål André Holme, Chief Physician at Oslo University Hospital and Clinical Investigator in Idogen’s study, and Dag Josefsen, who is Chief Physician and Head of Department at the Section of Cell Therapy.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/07/norwegian-doctors-prepare-for-idogens-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se